| Autor: |
Çalapkorur B; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Demirci E; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Baran O; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Ulusoy EK; Department of Neurology, Ankara City Education and Research Hospital, Ankara 38080, Turkey., Koçer D; Department of Biochemistry, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Demirelli S; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Gök M; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey., Şimşek Z; Department of Cardiology, Kayseri City Education and Research Hospital, Kayseri 38080, Turkey. |
| Abstrakt: |
Background/Objectives: Paroxysmal atrial fibrillation (PAF) is an important cause that is thought main potential factor in Embolic stroke of undetermined source (ESUS). Extended Holter ECG is an expensive and time-consuming examination. It needs another tools for predicting PAF in ESUS patients. In this study, serum galectin-3 levels, ECG parameters (PR interval, P wave time and P wave peak time) LA volume index, LA global peak strain and atrial electromechanical conduction time values were investigated for predicting PAF. Methods: 150 patients with ESUS and 30 volunteers for the control group were recruited to study. 48-72 h Holter ECG monitoring was used for detecting PAF. Patients were divided into two groups (ESUS + PAF and ESUS-PAF) according to the development of PAF in Holter ECG monitoring. Results: 30 patients with ESUS whose Holter ECG monitoring showed PAF, were recruited to the ESUS + PAF group. Other 120 patients with ESUS were recruited to the ESUS-PAF group. PA lateral, PA septum, and PA tricuspid were higher in the ESUS + PAF group ( p < 0.001 for all). Serum galectin-3 levels were significantly higher in ESUS + PAF than in ESUS-PAF and control groups (479.0 pg/mL ± 435.8 pg/mL, 297.8 pg/mL ± 280.3 pg/mL, and 125.4 ± 87.0 pg/mL, p < 0.001, respectively). Serum galectin-3 levels were significantly correlated with LAVI, PA lateral, and global peak LA strain (r = 0.246, p = 0.001, p = 0.158, p = 0.035, r = -0.176, p = 0.018, respectively). Conclusion: Serum galectin-3 levels is found higher in ESUS patients which developed PAF and Serum galectin-3 levels are associated LA adverse remodeling in patients with ESUS. |
